welcomes you to the new, improved website!Using data from the CoreValve US Expanding Use Study, outcomes for patients with end stage renal disease (ESRD) undergoing TAVR were evaluated using an endpoint of all-cause mortality or major stoke at 1 year. Mortality at 1 year was 30%, and the stroke incidence was 2.1%. New permanent pacemaker need was 27%. The 1-year mortality appears increased compared to patients without ESRD.
You are here:
One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease
Submitted by: Mark Ferguson
Source: Annals of Thoracic Surgery
Keywords:
Author(s): Daniel P. O’Hair, Tanvir K. Bajwa, Stanley J. Chetcuti, G. Michael Deeb, Robert C. Stoler, Robert F. Hebeler, Brijeshwar Maini, Mubashir Mumtaz, Neal S. Kleiman, Michael J. Reardon, Shuzhen Li, David H. Adams, Daniel R. Watson, Steven J. Yakubov, Jeffrey J. Popma, George Petrossian
